Swiss National Bank Buys New Holdings in Urogen Pharma $URGN

Swiss National Bank purchased a new stake in shares of Urogen Pharma (NASDAQ:URGN) in the first quarter, HoldingsChannel.com reports. The firm purchased 77,800 shares of the company’s stock, valued at approximately $1,399,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. SG Americas Securities LLC raised its holdings in shares of Urogen Pharma by 20.3% in the 1st quarter. SG Americas Securities LLC now owns 1,657,846 shares of the company’s stock worth $29,808,000 after purchasing an additional 280,199 shares during the period. Rice Hall James & Associates LLC grew its holdings in shares of Urogen Pharma by 8.8% during the 4th quarter. Rice Hall James & Associates LLC now owns 281,876 shares of the company’s stock worth $6,602,000 after purchasing an additional 22,733 shares during the period. Elmind Capital LP purchased a new stake in shares of Urogen Pharma during the 4th quarter worth about $2,342,000. DNB Asset Management AS acquired a new stake in Urogen Pharma during the 4th quarter worth approximately $397,000. Finally, UBS Group AG increased its position in Urogen Pharma by 30.2% during the 4th quarter. UBS Group AG now owns 235,040 shares of the company’s stock worth $5,505,000 after purchasing an additional 54,580 shares in the last quarter. 91.29% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts recently commented on URGN shares. LADENBURG THALM/SH SH initiated coverage on shares of Urogen Pharma in a report on Monday, May 11th. They issued a “buy” rating and a $43.00 price target on the stock. Jefferies Financial Group upgraded shares of Urogen Pharma to a “strong-buy” rating in a research note on Friday, April 24th. The Goldman Sachs Group reissued a “neutral” rating and issued a $44.00 price objective on shares of Urogen Pharma in a research report on Wednesday, July 15th. HC Wainwright reissued a “buy” rating on shares of Urogen Pharma in a research note on Thursday, July 9th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Urogen Pharma in a report on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Urogen Pharma presently has an average rating of “Moderate Buy” and an average target price of $41.62.

Insider Activity at Urogen Pharma

In other Urogen Pharma news, insider Mark Schoenberg sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $40.00, for a total value of $400,000.00. Following the transaction, the insider directly owned 119,763 shares of the company’s stock, valued at $4,790,520. This represents a 7.71% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 25,222 shares of company stock valued at $892,661 in the last 90 days. Insiders own 4.80% of the company’s stock.

Urogen Pharma Stock Performance

Shares of NASDAQ:URGN opened at $38.24 on Friday. The business’s 50-day simple moving average is $34.98 and its 200 day simple moving average is $26.29. The company has a market cap of $1.86 billion, a P/E ratio of -13.91 and a beta of 1.56. Urogen Pharma has a one year low of $15.86 and a one year high of $43.93.

Urogen Pharma (NASDAQ:URGN) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.01. The company had revenue of $50.96 million during the quarter, compared to analysts’ expectations of $44.83 million. Analysts predict that Urogen Pharma will post -0.76 earnings per share for the current year.

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.